Home / Market News / $VSTM
fiscal.ai Corporate Catalyst Impact 92/100 ● neutral

Verastem Oncology Reports Third Quarter 2026 Financial Results

Nov 5, 2026, 10:35 PM UTC · Primary ticker $VSTM

Verastem Oncology reported Q3 2026 financial results that significantly missed analyst expectations for both revenue and earnings per share. Despite the financial miss, the company highlighted positive clinical progress for its lead candidate and secured financing that extends its operational runway, creating a mixed signal for investors.

Verastem Oncology reported third-quarter 2026 financial results that were significantly below analyst consensus, with net product revenue of $24.0 million against estimates of $26.6 million, and an adjusted loss of $0.72 per share compared to a $0.47 loss. This substantial miss on key financial metrics is a negative catalyst for the company. However, the company also provided positive updates on its lead clinical candidate, VS-7375, noting antitumor activity, and secured financing that extends its cash runway into the first half of 2028, which mitigates some of the negative financial news. For traders, the immediate short-term impact is likely negative due to the earnings miss, but the extended cash runway and clinical progress could offer long-term opportunities if the Phase 3 trial for pancreatic cancer, planned for late 2026, shows positive results.

$VSTM negative Missed Q3 revenue and EPS estimates
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.